Tamarack Advisers, LP Collegium Pharmaceutical, Inc Transaction History

Tamarack Advisers, LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 15, 2023	SELL	$21.23 - $24.28 $4.03 Million - $4.61 Million	-190,000 Reduced 50.67%	185,000 $4.13 Million
Q2 2023 Aug 09, 2023	BUY	$21.06 - $24.0 $421,200 - $480,000	20,000 Added 5.63%	375,000 $8.06 Million
Q1 2023 May 10, 2023	SELL	$23.0 - $29.88 $736,000 - $956,160	-32,000 Reduced 8.27%	355,000 $8.52 Million
Q4 2022 Feb 10, 2023	BUY	$16.14 - $23.55 $1.4 Million - $2.05 Million	87,000 Added 29.0%	387,000 $8.98 Million
Q3 2022 Nov 14, 2022	BUY	$15.46 - $20.1 $3.09 Million - $4.02 Million	200,000 Added 200.0%	300,000 $4.81 Million
Q2 2022 Aug 16, 2022	BUY	$14.22 - $20.88 $1.42 Million - $2.09 Million	100,000 New	100,000 $1.77 Million

254

36.9M

100K

21.1K

Ticker COLL
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 34,126,200
Market Cap $1.12B
Description
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ...

Get notified when there are updates to the investment portfolio of Tamarack Advisers, LP, based on Form 13F filings with the SEC.

Stay updated on Tamarack Advisers, LP with notifications on news.